MRA Associates USA’s Gilead Sciences GILD Stock Holding History

MRA Associates USA’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-66	Closed	-$4.46K	–	128
2019 Q2	$4.46K	Buy	+66	New	+$4.34K	0.02%	124

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MRA Associates USA's GILD Position: Q3 2019 in Review

MRA Associates USA sold out of Gilead Sciences (GILD) in Q3 2019, closing a stake of 66 shares — an estimated $4.46K sold.

MRA Associates USA first reported a position in GILD in Q2 2019 and held it in 1 quarter. The position peaked at $4.46K in Q2 2019. 1,463 funds tracked by Wall St. Rank hold GILD as of Q3 2019.

MRA Associates USA reported no remaining Gilead Sciences position as of Q3 2019 after selling out during the quarter.
MRA Associates USA sold 66 Gilead Sciences shares in Q3 2019, an estimated $4.46K.
MRA Associates USA first reported a position in Gilead Sciences in Q2 2019 and held it in 1 quarter.
MRA Associates USA's Gilead Sciences position peaked at $4.46K in Q2 2019.
1,463 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2019.

Based on MRA Associates USA's 13F filing for Q3 2019, filed 8 Nov 2019.